SCHEMBL13759698

SCHEMBL13759698

Cc1ccc(S(=O)(=O)OC[C@H]2CC[C@@H](CO[Si](c3ccccc3)(c3ccccc3)C(C)(C)C)N2C(=O)OC(C)(C)C)cc1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.39
P2RX7 Q99572 2/20 0.38
HSD11B1 P28845 1/20 0.36
STS P08842 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
GPR119 Q8TDV5 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
NR1H2 P55055 1/20 0.34
LIMK2 P53671 1/20 0.33
ABCB1 P08183 1/20 0.33
GAA P10253 1/20 0.33
TSHR P16473 1/20 0.33
ADAM17 P78536 1/20 0.33
TGFBR1 P36897 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30586531 0.86 MMP13 (0.46) MMP13HSD11B1STSMEN1KMT2A
SCHEMBL31224155 0.84 ABCB1 (0.40) STSMEN1KMT2AGPR119ABCB1
SCHEMBL13759689 0.84 ABCB1 (0.40) STSMEN1KMT2AGPR119ABCB1
SCHEMBL1769258 0.82 ABCB1 (0.38) STSGPR119NR1H2ABCB1GAA
SCHEMBL29007758 0.82 ABCB1 (0.38) STSGPR119NR1H2ABCB1GAA
SCHEMBL17948125 0.82 ABCB1 (0.38) STSGPR119ABCB1GAA
SCHEMBL323498 0.82 MMP13 (0.43) MMP13HSD11B1STSMEN1KMT2A
SCHEMBL26361860 0.82 MMP13 (0.45) MMP13HSD11B1STSMEN1KMT2A
SCHEMBL31224004 0.81 ABCB1 (0.37) STSMEN1KMT2AGPR119ABCB1
SCHEMBL13759697 0.81 ABCB1 (0.35) STSGPR119ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560434-B2 AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. (US) 2009-07-14 US disclosed
US-7560434-B2 AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. (US) 2009-07-14 US disclosed
US-20070099942-A1 AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. (US) 2007-05-03 US disclosed
US-20070099942-A1 AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. (US) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099942-A1 AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases NSUN2, NSUN3, POLR2H MMP13 3623/4885P2RX7 1128/4885HSD11B1 2366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.